Treated neural tissue composition
View Patent ↗A treated composition of neural tissue is made of spinal cord tissue harvested from a spinal cord of a mammal. The spinal cord tissue is harvested from vertebral column of the mammal. The spinal cord tissue is harvested post mortem. The mammal is one of a primate, an equine, a bovine, a porcine or other mammalian animal. The spinal cord tissue is dried or has the water content in the tissue reduced or eliminated by freeze drying or hypothermic dehydration and treated with a cryopreservative.
1. A sterile, frozen package of dried, acellular composition of spinal cord tissue in the form of micronized particles and/or strands, suspended in cryoprotectant of poly-ampholyte solution, wherein the composition is free of dura mater; and wherein the composition has an inductive capacity when implanted into human recipients to induce host cells to produce new neural tissue.
2. The treated composition of claim 1 wherein the spinal cord had been placed in lactated Ringer's Solution or other suitable fluid and placed into a vapor phase of liquid nitrogen and the frozen spinal cord was transferred to a freeze dryer under vacuum to remove water, at completion of drying cycle the freeze dryer was heated to room temperature to avoid moisture condensation and the vacuum released to form a freeze dried spinal cord.
3. The treated composition of claim of claim 1 wherein the spinal cord tissue was cut into pieces from a freeze dried spinal cord to form freeze dried spinal cord tissue pieces prior to being suspended in the cryoprotectant and frozen.
4. The treated composition of claim of claim 3 wherein the pieces of the freeze dried spinal cord tissue were ground to form freeze dried spinal cord tissue micronized particles or cut or chopped to form freeze dried spinal cord tissue strands which may be branched or fragments.
5. The treated composition of claim 4 wherein the freeze dried spinal cord tissue micronized particles have a particle size greater than 50 microns or the strands or fragments have a length in the range of 1 to 6 mm.
6. The treated composition of claim 5 wherein the particle size of the micronized particles is about 100 to about 400 microns or the length of the branched strands or fragments is about 2 to 4 mm.
7. The treated composition of claim 6 wherein the spinal cord tissue is harvested from vertebral column of the mammal.
8. The treated composition of claim 7 wherein the spinal cord tissue is harvested post mortem.
9. The treated composition of claim 8 wherein the mammal is one of a primate, an equine, a bovine, a porcine or other mammalian animals.
10. The treated composition of claim 9 wherein the primate is a human.
11. The treated composition of claim 10 wherein the human post mortem spinal cord was excised aseptically without dura mater from the cadaver donor.
12. The treated composition of claim 1 wherein the freeze dried spinal cord tissue micronized particles or strands or fragments can be stored at room temperature prior to being treated by suspension in the cryoprotectant and frozen.
13. The treated composition of claim 12 wherein the freeze dried spinal cord tissue micronized particles or strands or fragments or combinations thereof are implanted into human recipients having neural cell or nerve damage.
14. The treated composition of claim 13 wherein the implanted composition of spinal cord tissue micronized particles or strands or fragments or combinations thereof after implantation initiates a cellular response of host cells and a reprogramming of host cells.
15. The treated composition of claim 14 wherein host cells infiltrate the composition and spread throughout the composition to form infiltrating host cells.
16. The treated composition of claim 15 wherein the infiltrating host cells exhibit and express nestin, Olig2 and beta-III tubulin markers with the capacity to initiate differentiation into neuronal or glial lineages.
17. The treated composition of claim 16 wherein the infiltrating host cells associated with the implanted composition have no expression of the marker Sox9 for osteogenic differentiation.
18. The treated composition of claim 17 wherein the freeze dried spinal cord tissue is processed to form an acellular material composition with the capacity to induce reprogramming of host cells into specific neural lineages.
19. The treated composition of claim 18 wherein the freeze dried spinal cord tissue when used as an implant transforms host cells to express neural lineage markers in the absence of forced reprogramming of host cells by expressed transcription factor needed to drive neural differentiation.
20. The treated composition of claim 19 wherein the freeze dried spinal cord tissue when used in an implant can be used as a neural treatment for repair of brain injury due to trauma or stroke or as a neural treatment for degenerative neural conditions.
21. The treated composition of claim 20 wherein the implant can be used to promote repair of nerve damage or to stimulate new nerve growth or both.
22. The treated composition of claim 1 wherein the spinal cord tissue was provided as fragments.
23. The treated composition of claim 22 wherein the fragments in suspension after being unfrozen for implantation were embedded in a bioabsorbable material for implantation.
24. The treated composition of claim 23 wherein the bioabsorbable material was a hydroxyethyl starch.
25. The treated composition of claim 1 wherein the spinal cord tissue is prepared by dehydration at hypothermic temperatures.
26. The treated composition of claim 1 wherein the spinal cord tissue is chemically dehydrated.